Date of birth: 05/09/1948

BIOGRAPHY

Stan Kaye qualified in medicine in 1972 in London and completed training in medicine and oncology in London and Australia. His career in oncology began in the 1970s, inspired by witnessing groundbreaking treatments for cancers like choriocarcinoma.

In 1985, he moved to the University of Glasgow, founding a clinical trials unit and the Scottish Gynecological Cancer Trials Group, focusing on drug resistance and translational research. In 2000, he established the Drug Development Unit at the Institute of Cancer Research in London, where his team pioneered treatments like the PARP inhibitor olaparib and abiraterone.

The author of over 350 peer-reviewed papers, Kaye sat on the editorial boards of 12 cancer journals during his career and has held various national and international responsibilities, most notably in Cancer Research UK (the world’s largest cancer charity) for which he previously chaired the Clinical and Translational Research Committee.

A dedicated mentor, Kaye shaped the next generation of oncologists. Even after retiring in 2014, he continues his contributions to cancer research and health services.